| Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer | TA1021 | | |
| Bevacizumab gamma for treating wet age-related macular degeneration | TA1022 | | |
| Meningitis (bacterial) and meningococcal disease | QS19 | | |
| Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) | NG245 | | |
| Eplontersen for treating hereditary transthyretin-related amyloidosis | TA1020 | | |
| Asthma pathway (BTS, NICE, SIGN) | NG244 | | |
| Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer | TA1017 | | |
| Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis | TA1018 | | |
| Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over | TA1019 | | |
| Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction | IPG794 | | |
| Elafibranor for previously treated primary biliary cholangitis | TA1016 | | |
| Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer | TA1014 | | |
| Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments | TA1015 | | |
| Endometriosis: diagnosis and management | NG73 | | |
| Menopause: identification and management | NG23 | | |
| Avapritinib for treating advanced systemic mastocytosis | TA1012 | | |
| Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices | DG61 | | |
| Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria | TA1010 | | |
| Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia | TA1013 | | |
| Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) | DG60 | | |
| Belzutifan for treating tumours associated with von Hippel-Lindau disease | TA1011 | | |
| Acute kidney injury: prevention, detection and management | NG148 | | |
| Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension | TA1009 | | |
| Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments | TA1008 | | |
| Burosumab for treating X-linked hypophosphataemia in children and young people | HST8 | | |
| Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer | TA1007 | | |
| Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) | TA1006 | | |
| Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over | TA1002 | | |
| Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over | TA1003 | | |
| Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion | TA1004 | | |
| Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement | TA1005 | | |
| Iptacopan for treating paroxysmal nocturnal haemoglobinuria | TA1000 | | |
| Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment | TA1001 | | |
| Vibegron for treating symptoms of overactive bladder syndrome | TA999 | | |
| Single-step scaffold insertion for repairing symptomatic chondral knee defects | IPG793 | | |
| Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma | TA997 | | |
| Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer | TA737 | | |
| Adrenal insufficiency: identification and management | NG243 | | |
| Risankizumab for treating moderately to severely active ulcerative colitis | TA998 | | |
| Phrenic nerve pacing for congenital central hypoventilation syndrome | IPG790 | | |
| Caval valve implantation for tricuspid regurgitation | IPG791 | | |
| Phrenic nerve pacing for ventilator-dependent high cervical spinal cord injury | IPG792 | | |
| Relugolix for treating hormone-sensitive prostate cancer | TA995 | | |
| Linzagolix for treating moderate to severe symptoms of uterine fibroids | TA996 | | |
| Diabetic retinopathy: management and monitoring | NG242 | | |
| Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal) | TA994 | | |
| Abaloparatide for treating osteoporosis after menopause | TA991 | | |
| Burosumab for treating X-linked hypophosphataemia in adults | TA993 | | |
| CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack | DG59 | | |
| Anaphylaxis | QS119 | | |